The widespread use of primaquine and tafenoquine for malaria eradication necessitates careful risk stratification, as these drugs are strong oxidants capable of inducing severe hemolysis in G6PD-deficient individuals (Sulistyaningrum et al., 2020; Mukherjee et al., 2015). Here, G6PD is linked to malaria.